$BHC BUYS. Good time for pharma!Key Stats:
Market Cap: $4.4B
Revenue (TTM): $11.82B
EBITDA Margi
Debt: $29.05B (High, but manageable with recent restructuring efforts)
Technical Indicators:
1️⃣ 50-Day and 200-Day Moving Average Crossover: BHC is trending above its 200-day moving average, showing long-term bullish momentum.
2️⃣ RSI Neutral : No signs of overbought territory, providing room for further upside without a pullback.
3️⃣ Strong Support Zone: Key support held firmly, suggesting bulls are defending this level.
Fundamental Indicators:
1️⃣ Valuation Play: BHC is undervalued relative to its industry, despite consistent revenues of $11.82B annually. The EV/EBITDA ratio of 8.1 confirms a bargain price.
2️⃣ Operational Efficiency: EBITDA margins at 34.5% and an operating cash flow of $1.01B indicate strong cash-generating ability, even under high debt loads.
3️⃣ Catalyst Potential: Patent dispute resolutions and potential drug approvals could act as significant tailwinds for revenue growth and investor sentiment.
Potential Path to Profit:
1️⃣ Lowest Risk: Buy shares outright at current levels.
Disclaimer: We are not a brokerage or investment firm. This is not financial advice. All sales are final.
